Incannex Doses First Patient in DReAMzz Phase 2 Study of IHL-42X
IXHL sits 34% above its 52-week low of $2.49 on light trading volume (0.3× avg).
Summary
Incannex announced the first patient has been dosed in its DReAMzz Phase 2 study of IHL-42X for obstructive sleep apnea, with all 14 trial sites now IRB-approved.
Key Events · Product Development and Regulatory · IXHL
-
First Patient Dosed in DReAMzz
The first patient has been dosed in the Phase 2 dose-optimization study of IHL-42X for obstructive sleep apnea, advancing the program from screening to active dosing.
-
All 14 Sites IRB-Approved
All 14 U.S. clinical trial sites now have Institutional Review Board approval to conduct the DReAMzz study.
-
Builds on Positive RePOSA Data
This follows Phase 2 RePOSA results showing statistically significant AHI reductions with individual reductions up to 83% and an exceptional safety profile.
-
FDA Fast Track Designation
IHL-42X holds FDA Fast Track designation, supporting more frequent FDA interactions and potential accelerated regulatory review.
Analysis · IXHL · Life Sciences
Dosing the first patient in the DReAMzz Phase 2 dose-optimization study marks a concrete clinical execution milestone for IHL-42X, the lead drug candidate for obstructive sleep apnea. This follows positive Phase 2 RePOSA results showing AHI reductions up to 83% and FDA Fast Track designation. The milestone confirms the trial is actively underway across all 14 U.S. sites, moving the program closer to Phase 3 development.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 29.6% of the 2856 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IXHL was trading at $3.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.3M. The 52-week trading range was $2.49 to $27.69. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.